Docetaxel Anhydrous
Who holds supplier records for Docetaxel Anhydrous? 7 organisations hold a current record for Docetaxel Anhydrous: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4), China (2) and United States (1).
Most records are filed under another form of this substance: Docetaxel (25 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Docetaxel Anhydrous: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/docetaxel-anhydrous
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Docetaxel Anhydrous expires 16 May 2036. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Docetaxel Anhydrous. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 24854 · latest filing Jun 2011
- Fujian South Pharmaceutical Co. Ltd.ChinaActive DMF 25295 · latest filing Sept 2011
- Hubei Haosun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 22562 · latest filing Feb 2009
- Intas Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 25495, 28756 · latest filing Oct 2014
- Laurus Labs LimitedIndia Company GMP cert on recordActive DMF 23138, 26595 · latest filing Oct 2012
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 27308 · latest filing Jul 2013
- PHYTON BIOTECH LLCUnited StatesActive DMF 24675 · latest filing Feb 2011
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (4)
Organisations whose Type II DMFs for Docetaxel Anhydrous are no longer active. These show a past filing, not current supply.
Show all 4 historical records
- South Korea · Inactive DMF 25672 · filed Jan 2012
- India · Inactive DMF 25142 · filed Aug 2011
- BENZOCHEM LIFESCIENCES PVT LTDInactive DMF 21275 · filed Jan 2008
- POLYMED THERAPEUTICS INCInactive DMF 20961 · filed Oct 2007
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (54 listed products contain Docetaxel Anhydrous). The latest listed patent expires 16 May 2036. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Docetaxel Anhydrous is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL92).
Chemical identity
- IUPAC name
- [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
- Canonical SMILES
- CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
- InChIKey
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N
- Synonyms
- Bind 014, Cabazitaxel metabolite (rp56976), CKD-810, Docefrez, Docetaxel anhydrous, Docetaxel, anhydrous, Docetaxel kabi, Docetaxel mylan, Docetaxel teva pharma, Docetaxel winthrop, NSC-628503, Rp56976
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Microtubule Inhibitor
- Physiologic effect
- Microtubule Inhibition
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Docetaxel Anhydrous?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Docetaxel Anhydrous: Dr. Reddy's Laboratories Ltd. (India), Fujian South Pharmaceutical Co. Ltd. (China), Hubei Haosun Pharmaceutical Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Laurus Labs Limited (India), MSN Laboratories Private Limited (India) and PHYTON BIOTECH LLC (United States). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Docetaxel Anhydrous Drug Master Files are active?
Dr. Reddy's Laboratories Ltd. (DMF 24854), Fujian South Pharmaceutical Co. Ltd. (DMF 25295), Hubei Haosun Pharmaceutical Co., Ltd. (DMF 22562), Intas Pharmaceuticals Ltd. (DMF 25495, 28756), Laurus Labs Limited (DMF 23138, 26595), MSN Laboratories Private Limited (DMF 27308) and PHYTON BIOTECH LLC (DMF 24675). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Docetaxel Anhydrous records mean?
4 organisations have only inactive Type II DMFs for Docetaxel Anhydrous. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Docetaxel Anhydrous?
Yes. The latest patent listed for an approved US product containing Docetaxel Anhydrous expires 16 May 2036, across 54 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Docetaxel Anhydrous supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Docetaxel Anhydrous?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.